ERBB2 and neoplasm: In most cases of ≥cT2 and/or clinical axillary involvement, and in selected cases of cT1c triple-negative and HER2-positive breast cancer, primary systemic treatment (PST) should be considered as an alternative to upfront surgery, despite an initial favorable tumor-to-breast ratio [5].